{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:34:05Z","timestamp":1780634045881,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"am","delay-in-days":306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.bone.2022.116343","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T19:06:08Z","timestamp":1643483168000},"page":"116343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial"],"prefix":"10.1016","volume":"157","author":[{"given":"Roland","family":"Chapurlat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gensburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Trolliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Rouanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Mehsen-Cetre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Orcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.bone.2022.116343_bb0005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1359\/jbmr.06s223","article-title":"G(s)alpha mutations in fibrous dysplasia and McCune-albright syndrome","volume":"21","author":"Weinstein","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116343_bb0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J","article-title":"The histopathology of fibrous dysplasia of bone in patients with activating mutations of the gs alpha gene: site-specific patterns and recurrent histological hallmarks","volume":"187","author":"Riminucci","year":"1999","journal-title":"J. Pathol."},{"key":"10.1016\/j.bone.2022.116343_bb0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.berh.2007.11.004","article-title":"Fibrous dysplasia of bone and McCune-albright syndrome","volume":"22","author":"Chapurlat","year":"2008","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.bone.2022.116343_bb0020","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1002\/jbmr.2894","article-title":"Prognostic factors from an epidemiologic evaluation of fibrous dysplasia of bone in a modern cohort: the FRANCEDYS study","volume":"31","author":"Benhamou","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116343_bb0025","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1210\/jc.2013-1823","article-title":"Hepatobiliary and pancreatic neoplasms in patients with McCune-albright syndrome","volume":"99","author":"Gaujoux","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2022.116343_bb0030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1359\/jbmr.2001.16.5.806","article-title":"Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia","volume":"16","author":"Collins","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116343_bb0035","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1097-0142(19940301)73:5<1411::AID-CNCR2820730516>3.0.CO;2-T","article-title":"Malignancies in fibrous dysplasia","volume":"73","author":"Ruggieri","year":"1994","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.bone.2022.116343_bb0040","article-title":"GNAS mutated thyroid carcinoma in a patient with mc cune albright syndrome","volume":"18","author":"Legrand","year":"2020","journal-title":"Bone Rep."},{"key":"10.1016\/j.bone.2022.116343_bb0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/jbmr.3286","article-title":"Increased risk of breast cancer at a young age in women with fibrous dysplasia","volume":"33","author":"Majoor","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116343_bb0050","article-title":"Fibrous dysplasia\/McCune-albright syndrome: a rare, mosaic disease of G\u03b1s activation","author":"Boyce","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2022.116343_bb0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13023-017-0629-x","article-title":"Determinants of impaired quality of life in patients with fibrous dysplasia","volume":"12","author":"Majoor","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.bone.2022.116343_bb0060","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/jbmr.3602","article-title":"Activation of RANK\/RANKL\/OPG pathway is involved in the pathophysiology of fibrous dysplasia and associated with disease burden","volume":"34","author":"de Castro","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116343_bb0065","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1172\/JCI118157","article-title":"Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption","volume":"96","author":"Greenfield","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2022.116343_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102884","article-title":"Role of IL-6 in bone destruction and bone repair in rheumatoid arthritis","author":"Takeuchi","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bone.2022.116343_bb0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.25053","volume":"62","author":"Garnero","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2022.116343_bb0080","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1111\/1523-1747.ep12874963","article-title":"Interleukin-6: molecular pathophysiology","volume":"94","author":"Sehgal","year":"1990","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bone.2022.116343_bb0085","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1359\/jbmr.1998.13.7.1084","article-title":"Increased interleukin-6 production in mouse osteoblastic MC3T3-E1 cells expressing activating mutant of the stimulatory G protein","volume":"13","author":"Motomura","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116343_bb0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI118773","article-title":"Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune\u2013Albright syndrome","volume":"98","author":"Yamamoto","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2022.116343_bb0095","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1359\/jbmr.1999.14.7.1104","article-title":"Glucocorticoids decrease interleukin-6 levels and induce mineralization of cultured osteogenic cells from children with fibrous dysplasia","volume":"14","author":"Stanton","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116343_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115784","article-title":"Bisphosphontes in the treatment of fibrous dysplasia of bone","volume":"143","author":"Chapurlat","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116343_bb0105","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1210\/jc.2018-02543","article-title":"Denosumab in patients with fibrous dysplasia previousy treated with bisphosphonates","volume":"104","author":"Majoor","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2022.116343_bb0110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jbspin.2014.04.013","article-title":"Transient improvement of severe pain from fibrous dysplasia of bone denosumab treatment","volume":"81","author":"Benhamou","year":"2014","journal-title":"J. Bone Spine"},{"key":"10.1016\/j.bone.2022.116343_bb0115","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","volume":"27","author":"Boyce","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116343_bb0120","first-page":"1729","article-title":"Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-albright syndrome: an observational study","volume":"3","author":"Meier","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116343_bb0125","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/rheumatology\/kex391","article-title":"Neuroendocrine and neurophysiological effects of interleukin-6 in rheumatoid arthritis","volume":"57","author":"Choy","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bone.2022.116343_bb0130","series-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","author":"et Liu","year":"2008"},{"key":"10.1016\/j.bone.2022.116343_bb0135","series-title":"Cross-over Trials in Clinical Research","author":"Senn","year":"2002"},{"key":"10.1016\/j.bone.2022.116343_bb0140","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S8756-3282(03)00064-4","article-title":"Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression","volume":"33","author":"Riminucci","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116343_bb0145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2004.03.004","article-title":"Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment","volume":"35","author":"Chapurlat","year":"2004","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:59:37Z","timestamp":1757613577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328222000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":29,"alternative-id":["S8756328222000199"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2022.116343","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2022.116343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116343"}}